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Abstract 
Using medications in the treatment of substance abuse disorders has become as an important part 
of available treatment options offered by medical practitioners.  In this paper data will be 
presented to show the benefits and barriers associated with using several types of medication-
assisted treatment to treat opioid use disorder.  There are three drugs approved by the FDA for 
the treatment of opioid dependence: Buprenorphine, Methadone, and Naltrexone.  There has 
been limited adoption of pharmacotherapies in the treatment of substance use disorders.  In 
treatment of addiction, medications are used to reduce the intensity associated with withdrawal 
symptoms, reduction of cravings for the substance, and help reduce the chance of continued use 
or relapse.  This is accomplished by blocking the effects of the drug.  Opiate treatment programs 
offer medication assisted treatment (MAT) to patients who have been identified with an opiate 
use disorder from a qualified professional.  Opioid treatment programs offer an array of services. 
The purpose of services includes reducing, eliminating, or preventing the use of illicit drugs; as 
well as reducing possible illegal action and the increase of communicable diseases including 
HIV.  The substance abuse and chemical dependency treatment field has been challenged to 
implement evidence-based practices.  There has recently been a dramatic increase in the number 
of interventions for substance use prevention and medication-assisted treatment is one of those 
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Introduction 
 The use of medications in the treatment for substance abuse has become a significant part 
of the treatment methods available to medical practitioners.  The drugs Methadone and 
Naltrexone have a relatively long history, but over the last ten years’ medications such as 
Buprenorphine, with this that could be called a superior plan of treatment are beginning to be 
more noticeable. (Roman, Abraham, & Knudsen, (2011).   
The website FDA (2019) outlines the three drugs approved for the treatment of opioid 
dependence as: Buprenorphine, Methadone, and Naltrexone.  All three treatment options have 
proven to be safe and effective when combined with counseling and psychosocial support.  Some 
individuals believe that people who seek treatment options for Opioid Use Disorders should be 
offered access to all three options.  Providing access allows providers of services to collaborate 
with clients to select a form of treatment suited to their personal needs.  Due to the chronic 
nature of Opiate Use Disorder, it is recommended that the need for continuing a medication-
assisted treatment program be re-evaluated periodically.  There is not a maximum recommended 
duration of services for maintenance treatment.  Some patients may choose to continue treatment 
indefinitely.   
The concern in the United States with the opioid epidemic continues to increase.  New 
treatments such as medication-assisted treatment programs have been met with concern by some 
and enthusiasm with others.  There has been a lack of adoption of these new practices and this 
paper will investigate the reasons behind those who believe in the treatment and those who are 
against it.   
Dangers of Opioids 
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Now more than ever, we are hearing of the misuse of prescription opiate pain medication. 
Experts of the field acknowledge that the abuse of these of drugs begun more than twenty years 
back. Throughout the United States, healthcare experts are giving significantly more 
consideration to this issue, and physicians are considering this when recommending opiates as a 
treatment option. Before taking them, one should learn as much as possible concerning these 
medicines. 
How Opiates work: 
Opiates are medications that reduce the strength of pain indicators in the patient’s brain. They 
also affect the areas of the brain which regulate an individual’s emotion, thus helping to reduce 
the effects of pain.  This is one of the reasons they can be habit forming. 
Opiates include: 
Oxycodone (OxyContin, Percocet), Hydrocodone (Vicodin): These potent opiates are the most 
commonly used for painful disorders such as broken bones, dental issues, and conditions such as 
cancer.  
Morphine: This is commonly used after a surgical procedure to lessen pain 
Codeine: This is commonly used for mild pain. It can be prescribed for other health issues such 
as coughs and severe diarrhea. 
Some shocking facts about opioids 
The consequences of opiates, involving their habit forming abilities, are a large factor to the 
more than 16,600 U.S. deaths from painkillers that happen every year. That is around 45 people a 
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day in emergency rooms across the United States.  And this does not include the people who 
have gone to the emergency room and survived the overdose. (CDC, 2018) 
Prescriptions for opiates have risen to 300 percent in the last decade or so. Vicodin and other 
hydrocodone-combination painkillers are the most commonly prescribed drugs in the United 
States. (CDC, 2018) 
The problem of opiate abuse first began in the late 1990s and by the year 2007, deaths from 
opiate overdose outstripped deaths from heroin and cocaine in the United States. (CDC, 2018) 
In more current years, hundreds of federal, state, and local mediations have been instigated in 
reaction to the opiate epidemic. Presently there is a national database that helps healthcare 
experts to monitor usage, deaths and other developing data. 
When misused, even one large dose can cause severe respiratory failure, which can lead to death. 
Nearly one third of females of child bearing age had an opiate prescription filled every year 
between the years of 2008 and 2012. Contact with opiates during pregnancy increases the risk of 
defects in the unborn child’s brain, heart, spine and abdominal wall. (CDC, 2018) 
Sometimes these painkillers do not even relieve the pain. Patients chronically using opiates could 
feel worse due to their side effects. Side effects can include: constipation, sedation and 
depression. Other patients experience aggravated pain after starting opiates. This is known as 
opioid-induced hyperalgesia. (CDC, 2018) 
Some numbers on amount of opiates prescribed yearly 
After a continual growth of the general national opiate prescribing frequency starting in 
the year 2006, the over-all number of prescriptions distributed peaked in the year 2012 to beyond 
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255 million and there was a prescription rate of 81.3 prescriptions for every 100 people. (CDC, 
2018) 
The general nationwide opiate prescription rate dropped in the years 2012 to 2017, and in 2017, 
the prescription rate fell to the least it had been in more than 10 years, being 58.7 prescriptions 
per 100 people, which is a whole of more than 191 million opiate prescriptions. (CDC, 2018) 
Nonetheless, in 2017, prescription rates continued to continue to be higher in specific parts of the 
United States. In 16% of counties in the United States, sufficient opiate prescriptions were 
prescribed for each person to have one. Whereas the complete opiate prescription rate in 2017 
was 58.7 prescriptions per 100 persons, other regions had amounts up to seven times as high as 
that. (CDC, 2018) 
According to the Substance Abuse and Mental Health Services Administration's National Survey 
on Drug Use and Health, a projected 1.9 million people in the United States qualify for abuse 
and dependence criteria for prescription pain relievers. Also, the Centers for Disease Control and 
Prevention report that yearly, more people die from prescription painkiller overdoses than from 
heroin and cocaine combined. (SAMH 2019) 
Long term effects of opiate use  
A 2012 study by AnGee Baldini, MD, Michael Von Korff, ScD, and Elizabeth H. B. Lin, MD, 
MPH found the following information:  The reprimand to decrease the abuse of prescription 
opiates was publicized by the U.S. Food and Drug Administration (FDA), National Drug Control 
Policy, The Drug Enforcement Agency. These organizations recommended physician education 
regarding opiate prescriptions. The recent motivation of change was compelled by the rising 
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number of deaths and overdoses reported by the Centers for Disease Control and Prevention. The 
prevalence of chronic pain has risen to 40% now in the countries contributing, with 10% to 25% 
of the populace suffering from substantial deficiency due to their chronic pain.  Using opiates to 
treat chronic pain that is not related to cancer is becoming more common subsequent to the 
endorsements given by numerous pain societies. The commonness of long term opiate use has 
steadily risen since the year 1980 with approximately 6-8 million people in the United States 
using opiates for the management of long term pain built on the stated use of long-lasting opiate 
therapy. With this extensive usage, there is a large amount of material on the consequences of 
opiates suitable for use by primary care doctors. This review does consider scientific studies 
published within the last six years providing data pertinent to the possible side effects of opiates.  
 
The information collected is accessible in an organ system methodology to enable 
training in the practice of primary care doctors. The goals are to improve the doctors’ abilities in 
discussing the side effects of opiates with their patients of whom are considering long term use 
for long-lasting discomfort, as well as to raise awareness of doctors and users in recognizing 
possible side effects that could be caused by the use of the opiate pain killers. (Baldini, Von 
Korff, & Lin, 2012) 
 
Method: The research for the data in the reports available in scientific periodicals in the years 
2005-2011 was directed utilizing Quality Clinical Guidelines, Medline Agency for Healthcare 
Research and Cochrane Database of Systematic Reviews and Evidence Based Reports. A review 
was implemented due to the large amount of publications related to the negative effects of 
opiates being normally trivial, and the multiplicity of negative effects across the systems 
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prevented a measureable evaluation. The organ systems included were the respiratory, immune, 
gastrointestinal, musculoskeletal, cardiovascular, endocrine, and the central nervous system. 
Inside each system, it was initially considered articles to meet criteria that included the words 
opiate and each organ system in the title, or body of each article. There were 1,974 initially 
identified articles, 74 of which incorporated verification of prolonged opiate abuse on each 
system that was identified. In the identified articles, there were 43 selected on the significance in 
prescribing by primary care doctors. Other articles identified by the experts’ recommendations 
and other related bibliographies supplemented the study. (Baldini, Von Korff, & Lin, 2012) 
 
Results: Gastrointestinal System Effects 
Constipation was one of the predominant negative effects of long term opiate therapy generally 
well-known by doctors and their patients as a negative outcome of opiate use. The 
pathophysiology of this progression outcomes from the stimulus of the opiate receptors in the 
digestive tract. Multiple studies have reported that up to 45% of patients using opiates experience 
constipation, while up to 25% also reported nausea. Constipation related to opiate usage still 
remains obstinate to treatment using laxatives and stool softener medications. Constipation 
reported had been severe enough that patients had to reduce the dosage of their medicine or stop 
opiate use completely. In the starkest examples, opiate abuse has been known to raise the 
possibility of bowel obstructions, which could result in being hospitalized and even demise. In 
supplement to the constipation and nausea, opiate use could trigger bloating, vomiting, and 
abdominal cramps. The risk of intestinal bleeding is comparable to nonsteroidal anti-
inflammatory (NSAID) medications. (Baldini, Von Korff, & Lin, 2012) 
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The negative consequences of these intestinal effects weigh significance for particular attention. 
Constipation can be related with other quality of life problems. Studies discovered that up to one 
third of constipated opiate users reported psychological suffering and increased frequency of 
being depressed related to the controlled patients. Patients with stomach complaints related to 
opiate use have considerably more hospital visits and hospital admission rates, longer stays while 
admitted in the hospital, and higher rates of primary care doctor visits. The linked damage to 
quality of life should be compared to opiate efficiency for their chronic pain. (Baldini, Von 
Korff, & Lin, 2012) 
Respiratory System Effects 
There has been a link between sleep breathing disorders and the use of opiates found in more 
current studies. Continuing opiate use is proven to be related to the symptoms of sleep disordered 
breathing, ataxic breathing, sleep apnea, hypoxemia, and also retention of carbon dioxide. With 
patients that were on opiate therapy for six months or longer, the commonness of mild to severe 
sleep disordered breathing has been proven to be up to 75%. Comparing, samples of the 
population, sleep disordered breathing is only detected in 3% - 20% of people. In another smaller 
study, sleep apnea was discovered in up to 30% of patients using methadone. Also as much as 
10% of patients using opiate therapy experience a type of hypoxemia. These adverse results of 
opiates seem to happen in a dependent of dose manner. Ataxic breathing was detected in as many 
as 92% of patients who were given a morphine dose of 200 mg, 61% of patients taking under 
200 mg, and in only 5% of patients that were not taking opiates. While the risk of death from 
opiate overdose has been established in other studies, death from sleep disordered breathing does 
need more research, as what studies that are available are usually small and contain misleading 
samples. (Baldini, Von Korff, & Lin, 2012) 
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Respiratory System Depression 
There are life threatening side effects of opiate medications such as bradycardia, respiratory 
depression, and hypotension, occurring during an opiate overdose. Though this is not completely 
comprehended, a physical tolerance to painkillers does not automatically compare to a tolerance 
of the results of opiates on the breathing system. Patients who were being prescribed larger doses 
of opiates were found to have proficiency in the increased risk of overdose. The estimations of 
this danger all differ, nonetheless more current documentation has established an 8.9% increase 
in persons using more than 100 milligrams daily, relative to persons receiving opiate treatment of 
fewer than 20 milligrams daily.  And a 3.7 % rise amongst people using more than 50 milligrams 
daily.  Among patients prescribed higher opiate dosages, the danger of opiate overdosing can be 
projected to be 1.8% for each year of opiate use. Furthermore, 12% of overdoses resulted in 
death, proposing a yearly overdose possibility of 2 per 1,000 individuals per year among patients 
on high dose opiate treatment. The approximations were even with Centers for Disease Control 
and Prevention mortality information related to deaths from opiate overdose. Which are almost 
equivalent to car accidents as one of the prominent causes of death of 35–54 year olds. (Baldini, 
Von Korff, & Lin, 2012) 
Cardiovascular System Effects 
A recent analysis amongst elderly people suffering from arthritis discovered that opiate 
painkillers were paralleled to NSAID medications such as ibuprofen, opiate therapy was linked 
to a 77% increased risk of cardiovascular occurrences such as heart failure. During the initial 30 
days, the risk of cardiovascular occurrences was comparable with most opiates. Conversely, 
following 180 days of being on codeine, treatment was coupled with up to a 62% upsurge in 
RUNNING HEAD: MEDICATION-ASSISTED TREATMENT 13 
these opposing actions as paralleled to hydrocodone treatment. Another large study examining 
health insurance claims showed increased risks of myocardial infarction and cardiovascular 
revascularization among patients on opiate therapy relative to people not using opiates.  All the 
results of opposing cardiovascular properties of opiates could be described by the possible 
prejudices in investigation and may need to be repeated.  It cannot be presumed that opiates have 
lower cardiotoxicity than COX-2 inhibitors in the nonexistence of data supporting this 
assumption. (Baldini, Von Korff, & Lin, 2012) 
Central Nervous System Effects 
A noteworthy problem, especially among elderly users is Opiate neurotoxicity. Dizziness and 
sedation are additional properties that could potentially result in unintentional penalties amongst 
patients getting indefinite opiate treatment, such as breaks, painful falls, respiratory distress.  
Hyperalgesia related to extreme sensitivity to pain has been described in people on opiate 
regimens. Also, patients on opiate medications are shown to develop elevated levels of 
depression of around 38%. Intriguingly, it has been shown that people on opiates with emotional 
illness have a suggestively superior amounts of hospital stays. Associated use of central nervous 
system depressants such as barbiturates, and alcohol magnify respiratory depression and can 
result in potential apnea. (Baldini, Von Korff, & Lin, 2012) 
Musculoskeletal System Effects 
One of the important unfavorable effects of opiate painkillers are their relationship with the 
elevated possibility for fractures. However, the main reason for this increased risk is not clearly 
comprehended, the dominant idea is that opiates do lead to an elevated potential for tumbles 
across the central nervous system such as dizziness and decreased alertness. New studies report a 
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related risk of breaks at about 1.4 for elderly people who are utilizing opiate medications. 
Nonetheless, other approximations have positioned the threat ratio for amplified breakage at 
close to 4.9 when associating people using opiates to the age related controls who were 
prescribed NSAIDs. While the comparative risk is humble at best, because the rates of fractures 
are greater among elderly adults, the total increase in fracture risk is very prominent. In the 
population of over age 65-year-old, opiate medications bestowed a risk of 1.6 for fractures. New 
studies have found that propoxyphene and morphine greater than 50 mg daily doubled the risk of 
fractures in elderly patients, with an annual fracture rate of 9.95%. Also, higher amounts of 
opiates communicate to a elevated fracture possibility amongst elderly patients. Another study 
uncovered that shorter acting opiates carry higher fracture risk than longer acting opiates inside 
the beginning two weeks being used. (Baldini, Von Korff, & Lin, 2012) 
Almost all recent studies related the necessity for more examination of the elevated risk for 
fractures. Although the number of fractures has gradually decreased, the overall rate for death is 
remaining at a high rate of 21.9% per 1 year.  Additionally, patients who do survive a related 
event more often do not regain their highest quality of life. They more often have declines in 
their mental and physical health, and also may require institutional or long term care facilities. 
They also have diminished quality adjusted years of life. With respect to other analgesic 
therapies, opiates displayed a substantial rise in fractures when paralleled to other medicines like 
NSAIDs. (Baldini, Von Korff, & Lin, 2012) 
Endocrine System Effects 
Long term opiate use has been proved to have an effect on the endocrine system of both the male 
and female. The apparatus of these results is supposed to happen through contact with the 
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hypothalamic pituitary adrenal axis. Opiate pain killers have been proven to disturb the release of 
all the hormones including the anterior pituitary including adrenocorticotropic hormone, growth 
hormone, thyroid-stimulating hormone, prolactin, and the lutein-stimulating 
hormone. Individuals using long term opiate therapy have been shown to have a hyperactive 
functioning hypothalamic-pituitary-adrenal axis supplemented by the decreased functioning of 
the hypothalamic-pituitary-gonadal axis. With all of the enteropathies perceived, some of the 
weightiest pertain to the decrease of the gonadotropin-releasing hormone. (Baldini, Von Korff, & 
Lin, 2012) 
The reduction in the gonadotropin hormone can be apparent in male patients as 
hypogonadism, recognized as opiate induced androgen deficiency, fatigue, sexual dysfunction, 
infertility, and also related to decreased levels of testosterone. The decrease of testosterone is of 
special concern because introductory studies suggest the increased risk of metabolic syndrome 
and insulin resistance. (Baldini, Von Korff, & Lin, 2012) 
The reduced pulsatile release of gonadotropin-releasing hormone and the succeeding reduction in 
luteinizing and follicle stimulating hormones can have potential effects in females also. Reduced 
quantities of estrogen, low follicle stimulating hormone, and more amplified prolactin could 
result in osteoporosis, or other conditions such as galactorrhea. These initial conclusions propose 
the need for thoughtfulness when prescribing to people with pre-existing disorders. It is known 
that these side effects are usually changeable with discontinuation of medication or by lowering 
the dosage.  (Baldini, Von Korff, & Lin, 2012) 
Immune System Effects 
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Many kinds of opiates, such as morphine and fentanyl, are proven to have immunosuppressive 
effects. Studies of these effects are challenging to calculate, as precise tools are needed for 
additional examination. It is known that these opiates affect the opiate receptors on all of the 
immune cells. They could also moderate the immune function subtly through glucocorticoids 
discharged by the hypothalamic-pituitary-adrenal axis and norepinephrine that is released by the 
sympathetic nervous system. More current studies have exposed an upsurge in pneumonia risk in 
elderly people on long term opiate treatment. (Baldini, Von Korff, & Lin, 2012) 
 
How is opiate addiction treated? 
Opiate treatment programs and services vary by each provider and by the type of services needed 
to effectively address each patient’s needs. According to The Hazelden Betty Ford Foundation, 
here are some of the key components of successful opioid addiction treatment. (The Hazelden 
Betty Ford Foundation, 2019) 
Dialectical Behavioral Therapy (DBT) 
This treatment approach emphasizes behavioral change, problem-solving and emotional 
regulation, validation, mindfulness and acceptance 
Cognitive Behavioral Therapy (CBT) 
This form of treatment focuses on exploring patterns of thinking that lead to self-destructive 
actions, identifying beliefs that direct thoughts, and learning to modify these patterns of 
thinking to improve person’s coping skills 
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Acceptance and Commitment Therapy (ACT) 
This technique uses mindfulness and behavioral activation to increase psychological 
flexibility and the ability to engage in values-based, positive behaviors while experiencing 
difficult thoughts, emotions or sensations 
Motivational Enhancement and Interviewing 
This is a collaborative approach that helps patients identify their benefits with regard to 
staying sober, working through difficult issues, and developing skills necessary to 
accomplish their goals 
Medication-Assisted Therapies (MAT) 
Medications are now used to treat substance use disorders related to opioids and alcohol, 
helping ease withdrawal symptoms and reduce drug cravings. Use of medication-assisted 
treatment for opioid dependence with naltrexone and buprenorphine/naloxone is supported 
by scientific research and recommended by the U.S. Department of Health and Human 
Services Substance Abuse and Mental Health Services Administration (SAMHSA), National 
Institute on Drug Abuse (NIDA), Washington Circle, and the Veterans Administration.  
Mental Health Services 
More often than not, addiction comes with complicating factors such as depression, anxiety 
and trauma. These are also known as co-occurring disorders. With such complex conditions, 
the most effective approaches to care integrate treatment for the addiction and  the mental 
health so that both issues are being addressed at the same time. Services may include 
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individual or group therapy, family therapy, diagnostic assessments or medication 
management. Each type and frequency of care is determined by initial and ongoing 
assessments. 
Contingency Management/Motivational Incentives (CM) 
Incentive based interventions also known as tangible rewards are used to reinforce positive 
behaviors, increase addiction treatment retention and promote abstinence from drug abuse.  
Interpersonal Therapy (IPT) 
This is a short-term, limited focus treatment for depression and anxiety. 
Solution Focused Brief Therapy/Solution Focused Therapy  
This is a goal oriented therapy focusing on the individual’s present and future, rather than 
past. This is considered goal-oriented therapy.  
Mindfulness-Based Cognitive Therapy (MBCT) 
This technique is used to help prevent depression relapse; it works especially well for those 
suffering from major depressive disorder 
Educational Groups and Lectures 
This therapy focus on educating people about disorders and developing coping strategies 
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Twelve Step Facilitation (TSF) 
Originally designed as a system to actively engage patients in abstinence based support 
groups such as Alcoholics Anonymous, the interventions today are more widely utilized to 
help patients achieve and sustain recovery from both substance use disorders and their co-
occurring conditions 
Other Therapies 
Other treatment approaches may include many other therapies that complement care 
programs and services, such as: 
• Animal-Assisted Programming 
• Relapse Prevention Skills Group 
• Communications Training 
• Recovery Management Skills Building 
• Stress Reduction Skills Training 
• Yoga 
• Spiritual Care 
• Emotional Regulation 
• Distress Tolerance Skills Training 
• Experiential Therapy 
• Process Focused Group Therapy 
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(The Hazelden Betty Ford Foundation, 2019)  
 
In this paper we explore Medication assisted treatment, commonly known as MAT.  
Evidenced Based-Practices 
 Research is a systematic investigation involving the interpreting, collecting, and 
analyzing of information in a sequential manner for the purpose of increasing an individual’s 
understanding of the phenomenon of interest.  Each characteristic of interest and all aspects of 
the environment where the information resides must be defined clearly in order to be confident in 
what we find is real.  The process of collecting and organizing the data should be conducted and 
reported with the most possible precision.  This will allow other researchers to reproduce and 
verify the validity of findings.  The purpose of research is to inform the profession and enhance 
the ability to use best-practice methods (Sheperis, Young, & Daniels, 2017).   
Evidence-based programs and practices (EBPPs) are specific techniques and intervention 
models that have shown to have beneficial effects on results through arduous evaluations.  
Evidence-based practice is a process that brings together expertise from professionals, the top 
available research, and input from individuals to identify services demonstrated to achieve 
positive outcomes (Family and Health Services Bureau 2006).   
 Limited topics in opiate treatment have more importance than the importance of 
implementing evidence-based programs.  There is remarkable consensus among leaders within 
the field of addiction treatment about the importance of treatment programs’ willingness to adopt 
particular innovations (Roman et al., 2011).  Evidence-based practices and research can help 
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enhance the quality of treatment for substance use disorders by reducing or eliminating the 
ambivalent attitudes towards treatment with medication assisted treatment.   
 According to the Family and Health Services Bureau (2006), individuals may think the 
use of evidence-based programs and practices de-emphasizes decisions based on opinion, 
authority, or experience.  However, utilizing these programs simply means that the best available 
research is identified and combined with other factors for the best results.  Most advocates of 
evidence-based research programs do not diminish their importance associated with experience.  
They believe they should be integrated with experiences and resources which agencies and 
practitioners bring to practice.  Additionally, numerous funding entities require the agencies to 
document outcomes and identify evidence-based practices and programs that have been utilized.   
 Certain policies have utilized modest recording of the adopted behaviors as the standard 
for compliance to new criteria because accomplishment of the goal for enriching treatment 
quality through innovation is defined by larger degrees of adoption of behavior by treatment 
organizations.  However, evidence-based practices cannot be placed in one generic category as a 
measure for the quality of treatment because there has been no attention given to longer term 
application and the degree to which it really tails after acceptance (Roman et al., 2011).   
 There is yet to be an accepted typology to categorize evidence-based practices related to 
substance use disorder treatment.  Yet, there is no doubt that they are not alike in their 
likelihoods for application inside opiate treatment agencies.  Requirements for change within 
organizations regarding the object of evidence-based practices and programs varies widely.  
Some implementations flow easily and others can have the potential to cause major disruptions 
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in the delivery of treatment within the organization.  Some innovations directly affect the client 
and others have no direct effect on the client care (Roman et al., 2011).   
 Medication-assisted treatment in combination with counseling and behavioral therapies 
can help individuals sustain recovery.  More can be done to facilitate treatment options and 
develop additional therapies for individuals suffering with an Opioid Use Disorder diagnosis.  
Some clients may choose to continue maintenance indefinitely which is the cause of concern for 
some practitioners for fear the client has simply swapped one addiction for another.  Others 
argue that addiction is considered a disease, so why not use medication to treat and manage that 
disease like you would any other.    
The contrast between traditional psychosocial and pharmacological advances captures 
little.  Long-term treatment success is perhaps achieved by facilitating acceptance of medication-
assisted treatment programs, implementation of pharmacological treatment, psychosocial 
interventions, and multiple psychosocial considerations.  Recent empirical effectiveness of 
buprenorphine drugs like Suboxone appears to challenge this assumption (Roman et al., 2011).   
FDA Approved Drugs for Treatment 
FDA-approved buprenorphine products approved for the treatment of opioid dependence 
include: 
Bunavail (buprenorphine and naloxone) buccal film 
Cassipa (buprenorphine and naloxone) sublingual film 
Probuphine (buprenorphine) implant for subdermal administration 
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Sublocade (buprenorphine extended‐release) injection for subcutaneous use 
Suboxone (buprenorphine and naloxone) sublingual film for sublingual or buccal use, or 
sublingual tablet. 
Subutex (buprenorphine) sublingual tablet 
Zubsolv (buprenorphine and naloxone) sublingual tablets 
FDA-approved methadone products approved for the treatment of opioid dependence 
include: 
Dolophine (methadone hydrochloride) tablets 
Methadone (methadone hydrochloride) oral concentrate 
FDA-approved naltrexone products approved for the treatment of opioid dependence 
include: 
Vivitrol (naltrexone for extended-release injectable suspension) intramuscular (FDA, 
2019). 
Suboxone 
Suboxone, once thought to be a miracle drug to treat opiate addiction, is actually causing 
an epidemic in its own right. Suboxone is a mixture of buprenorphine, a semi-synthetic opioid, 
and naloxone, an opiate blocker. Suboxone has become overprescribed by medical professionals 
to an uninformed patient population. 
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Suboxone was first approved for use in the United States in 2003. Conclusions validate 
that the drug was formerly favored by the FDA to be used as a medication to aid opiate 
addicted patients with the uncomfortable symptoms associated with withdrawing from opiates. 
The use of the suboxone was designed to aid opiate addiction patients in a medical office 
setting, to help overcome opiate addiction. Conversely, it seems that many medical practitioners 
began to see the commercial profits of Suboxone being used as an opiate maintenance program, 
and ignoring the long term effects. For this reason, some patients have been enrolled in a 
Suboxone program for multiple years, as many as 10 or more. 
Patients were attempting to overcome addictions to powerful narcotics such as heroin and 
OxyContin and many doctors offered Suboxone as the answer. However, regardless of the 
justifications or rationalizations from many within the medical and addiction treatment field, the 
basic premise of a Suboxone maintenance program is trading one illegal drug for a legal drug. It 
is saying “take this pill and you’ll be okay” or “take this pill and it will take care of your 
addiction.” Basically, patients going into a doctor’s office to find a way to “overcome their 
addiction” are years later finding themselves still physically dependent and addicted to a 
substance. Suboxone keeps opiate withdrawal symptoms at bay, but does not offer any actual 
treatment and clearly does not offer a solution for overcoming addiction. Take the Suboxone 
supply away from a person on a Suboxone maintenance program and there is little doubt that 
they will turn to heroin or OxyContin or another form of opiate once withdrawal symptoms 
begin. This is not the patients fault- they were sold a faulty bill of goods by many of those people 
prescribing Suboxone. 
Hopefully, a competent and informed doctor will explain that a patient needs treatment 
for their psychological and emotional issues as well, and a competent doctor will be informed of 
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the physical effects of long term Suboxone use, but the question is how many doctor’s are 
uninformed and therefore unable to give this necessary information to their patients? Patients 
being prescribed Suboxone were told this prescribed medicine would be the solution to their 
problem of drug addiction. In addition to the fact that a patient is still physically dependent on a 
substance to function, there are several disturbing effects of Suboxone that are rarely discussed. 
Suboxone and Its Side Effects 
Since Suboxone is often being prescribed by physicians that are not trained in addiction 
medicine and in the treatment of addiction, there are many issues go unobserved and are not 
regulated. Suboxone utilized as medication for treatment of opiate detox is first-rate. In the hands 
of a properly trained practitioner, Suboxone makes opiate detox significantly more comfortable. 
Suboxone is an outstanding treatment in assisting opiate addicts throughout their withdrawal 
symptoms. Conversely, the long term use of Suboxone may cause a multitude of medical 
problems. Additionally, numerous Suboxone users report getting sober from the Suboxone is 
more challenging other opiate medications. Since normal opiate detox lasts 5-7 days Suboxone 
may stay in the system for as many as 9 days.  Withdrawal from Suboxone may take weeks to 
many months and will only bring painful physical systems and possibly more disturbing mental 
health problems. Patients often report depression and anxiety. Many report that withdrawing 
from the use of Suboxone, may last weeks and even months. 
Suboxone in the Long Term, Is it Safe? 
Suboxone use in the long term will cause withdrawal symptoms such as: anxiety, nausea 
depression, restlessness, sweats, fatigue, joint and muscle pain, insomnia, loss of libido, lack of 
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motivation. Opiate withdrawal symptoms normally last about one week, Suboxone withdrawal 
may last for some weeks or even months.  
 
Methadone 
Methadone has been used for decades to treat people who are addicted to heroin and 
narcotic pain medicines. When taken as prescribed, it is safe and effective. It allows people to 
recover from their addiction and to reclaim active and meaningful lives. For optimal results, 
patients should also participate in a comprehensive medication-assisted treatment (MAT) 
program that includes counseling and social support. 
Methadone decreases opiate cravings and withdrawing and blocks the effects of illegal 
opiates. Methadone may be prescribed as liquid, powder or wafer  and is taken once a day. 
Methadone is effective in higher doses, particularly for heroin users, helping them stay in 
treatment programs longer. 
As with all medications used in medication-assisted treatment (MAT), methadone is to be 
prescribed as part of a comprehensive treatment plan that includes counseling and participation 
in social support programs. 
Patients taking methadone to treat opioid addiction must receive the medication under the 
supervision of a physician. After a period of stability (based on progress and proven, consistent 
compliance with the medication dosage), patients may be allowed to take methadone at home 
between program visits. By law, methadone can only be dispensed through an opioid treatment 
program (OTP)certified by SAMHSA. 
The length of time in methadone treatment varies from person to person. According to 
the National Institute on Drug Abuse Publication Principles of Drug Addiction Treatment: A 
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Research-Based Guide – 2012 (PDF | 391 KB), the length of methadone treatment should be a 
minimum of 12 months. Some patients may require treatment for years. Even if a patient feels 
that they are ready to stop methadone treatment, it must be stopped gradually to prevent 
withdrawal. Such a decision should be supervised by a doctor. 
 
Naltrexone 
Naltrexone, commonly known by its brand name Vivitrol is an antagonist or opiate 
blocker medication. Antagonists form an obstruction that blocks opiate particles from connecting 
to the opioid receptors. Antagonists attach to opioid receptors, but do not result in the release of 
dopamine. They are not addictive and will not result in any type of physical dependence. 
 Vivitrol blocks opioid receptors in the brain for one month, helping patients prevent 
relapse to opioid dependence, following opioid detox. Patients must be opioid-free before 
starting Vivitrol. 
New study backed by the National Institute on Drug Abuse (NIDA) exposed that the 
relapse rates among adults with a history of opiate dependence were lower for patients receiving 
extended-release naltrexone than for those receiving treatment as usual (brief counseling and 
referrals for community treatment programs). Administered as a monthly injection, Vivitrol is an 
FDA-approved sustained-release, opioid antagonist for the prevention of relapse to opioid 
dependence. (NIH, 2016) 
This study is the initial big randomized trial of naltrexone versus usual care conditions 
among adults. The results presented that at 24 weeks (six monthly injections) of extended-release 
naltrexone resulted in a considerably lower opioid relapse rate (43 percent to 64 percent) 
between the two groups. Furthermore, while there were no overdoses observed in the extended-
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release naltrexone group, there were seven in the usual care group, with three resultants in 
deaths.  (NIH, 2016) 
Opiate Addiction Truth 
Many believe opiate addicts are seen as being hopeless by many within the medical field. 
The potential for relapse for opiate addicts is so high and the rate of overdose is higher than any 
other drugs in addiction treatment. Usually, opiate addicts that seek treatment and succeed at 
having some time away from opiates end up using opiates again, and because of the decreased 
tolerance this often results in an overdose. Many addicts die from this. For this reason, 
medication assisted treatment such as Suboxone or methadone is often used by doctors and 
treatment centers as “harm reduction”. 
The resulting facts are that these practitioners do not look at an opiate addict as someone 
that can ever succeed at sobriety, but more so as a number that they are trying save from being in 
the overdose statistics. Such as, “that girl could certainly not get sober so we should try to keep 
her from overdosing and dying.” This may seem like a brilliant belief, but here are two main 
issues: 
This knowledge is underestimating the addict’s willingness and ability to get clean. 
Treating with this harm reduction theory instead if offering them complete addiction 
treatment seems to be uneducated and shows diminutive understanding of addiction. This may be 
true or that, or the doctor is simply looking to cash in on profitable side of medication assisted 
treatment to keep someone on maintenance treatment than helping them get clean and sober by 
giving them effective addiction treatment. 
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Suboxone is the facilitator for this new maintenance treatment model and may actually be 
causing more damage than benefits. More addicts than ever are being prescribed Suboxone and 
getting less and less real treatment and never improving their quality of life. Regularly they 
substitute opiate abuse with another problem, such as with drinking alcohol or by using other 
drugs, or engaging in other high risk behaviors. More often many are still suffering with 
emotional distress or trauma that has not been resolved. When these persons definitively 
understand that the amazing wonder drug Suboxone has manifested into a completely new 
addiction and they want to stop use, they will find it more difficult to do than the opiates they 
were initially recovering from. 
But also, many experienced, educated clinicians that employ Suboxone properly, pair it 
with effective treatment and use a complete look at each patient and their individual situations. 
There are may be some cases when Suboxone maintenance best or only solution for the patients’ 
condition. However, these are very few cases. Normally, numerous physicians recommending 
Suboxone are doing this without requiring any type of ample treatment. Furthermore, numerous 
physicians that recommend Suboxone need less than an appointment and a payment for a person 
to receive their suboxone. Many times, after the first visit, the doctor will prescribe the suboxone 
after only a short second visit. This definitely should not be comprehensive addiction treatment. 
This is absolutely not recovery based therapy in any definition. 
Opiate Abuse in Today’s Youth 
  Abuse of opiates, is one of the most rapidly developing addiction problems in the United 
States. In 2016 there were a reported 3.6 percent of pubescents aged from 12 to 17 abusing 
opiates. The statistics are doubled among older juveniles and younger adults aged 18 to 25. The 
majority of this issue is due to prescribed opiates and not from heroin. (HHS, 2019) 
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According to The U.S. Department of Health and Human Services (2019) opioid abuse is 
declining. Among high school seniors, past-year misuse of prescription opiates lessened from a 
peak of 9.5% in the year 2004 to 3.4% in the year 2018. The misuse of  the drug Vicodin reduced 
from an all-time high of 10.5% in the year 2003 to 1.7% in the year 2018.  The misuse of 
OxyContin decreased from 5.5% in the year 2005 to 2.3% in the year 2018. (HHS, 2019) 
 
Additionally, children in 12th grade agree that opiates are more difficult to get access to 
than in years past. In the year 2010, 54% of 12th graders agreed that these medications were more 
easily obtainable, as paralleled to 32.5% in the year 2018. Overdose is the most serious 
significance of any type of drug abuse, especially opiates. Although the number of drug overdose 
deaths are still lower in general, the rate of overdose deaths among youth is still on the rise. In 
the year 2015, 4,235 young people aged 15 to 24 were declared dead from drug overdoses and 
more than half were attributed to opiates. (HHS, 2019) 
 
 
All adolescents are at risk for misusing opiates. Although, there are a wide range of 
factors that can either increase the risk of prescription drug misuse or help protect against it. For 
example:  
• Individuals at increased risk of opioid misuse include those with: acute and chronic pain, 
physical health problems, or a history of mental illness or other substance use or misuse. Youth 
who have witnessed a family member overdose or who have friends who misuse prescription 
drugs also are at highest risk. Data shows that almost half of adolescents aged 12 to 17 reported 
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misusing prescription pain relievers and reported that they were free or purchased them from a 
friend or even a family member. This reported rate is more than half for young adults aged 18 to 
25 who reported their misuse of pain relievers. (HHS, 2019) 
• Youth at the lowest risk were those who are committed to getting good grades, and going to 
college and those who are educated about the dangers of prescription drug abuse. Furthermore, 
young people who have a stronger relationship with their parents and whose parents do not 
approve of substance use are also at a lower risk of misuse. (HHS, 2019) 
MAT for Youth  
Using MAT such as Suboxone can be used in 2 primary ways: 
1. As a short course of treatment to reduce the complications of opiate withdrawal. 
2. As a longer course of maintenance treatment  
 
Though younger opiate users are at higher risk for overdose and other serious effects, 
since teenage users rarely have lengthy use histories, they are not necessarily great candidates for 
long-term Suboxone maintenance treatment. 
According to a SAMHSA (2018) expert consensus panel, for adolescent opiate dependent users:  
1. A short course of Suboxone for detoxification followed by continuing treatment with naltrexone 
is the preferred treatment to start with. 
2. If, after detox with Suboxone and continuing treatment with naltrexone, relapse occurs, then 
Suboxone maintenance treatment becomes more appropriate. 
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Opiate Abuse in The Elderly  
One population usually overlooked for substance abuse is the elderly many of whom are on these 
medications for chronic pain, places them at high risk of abuse. Prescription opiate abuse affects 
up to 17% of adults over the age of 60 according to the National Institute on Alcohol Abuse and 
Alcoholism (2019). Due to inadequate information, very little data, and rushed office visits, 
prescribers, abuse among the elderly often goes unnoticed. This is worsened by the circumstance 
that elderly people often have medical or mental disorders that imitate indicators of substance 
abuse, such as depression, diabetes, or dementia. (NIAAA,2019) 
According to the Office of Alcoholism and Substance Abuse Services, substance abuse 
among senior citizens can be categorized into two forms: the “hardy survivor,” or those who 
have been abusing substances for numerous years and have reached age 65, and the “late onset” 
group, which is those who form addictions later in life. (NIAAA, 2019) Medication assisted 
treatment such as methadone can be considered as a viable option for seniors experiencing 
prescription opiate abuse or seniors who are experiencing chronic pain.  
There are numerous factors that lead to turning to substance abuse later in life. These 
could be health correlated problems or life changing traumas that take an emotional toll. These 
events may provoke substance-abusing behavior that can result in a total substance abuse.  
Possible risk factors for drug addiction in the elderly include: 
• Retirement 
• Death of a family member 
• Death of a spouse, pet or close friend 
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• Loss of income or financial strains 
• Relocation or placement in a nursing home 
• Insomnia 
• Family discord  
• Decline in mental or physical health  
(NIAAA, 2019) 
 
Benefits of Medication Assisted Treatment 
Benefits of Methadone include: 
• Easy induction 
• Lower medication costs  
• High retention rates 
• Lowers drug use  
• History of successful use in pregnant women  
(Williams, 2018) 
Benefits of Suboxone include: 
• Minimal overdose risk 
• Flexible dosing  
• Excellent pain control 
• Better outcomes in newborns  
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• Less stigma 
• Injectable forms are being created  
(Williams, 2018) 
Benefits of Vivitrol include: 
• Relieves cravings 
• No fear of withdrawal symptoms  
• Blocks opiate use of any kind 
• Twice as successful in extended release injectable form   
(Williams, 2018) 
Disadvantages of Medication Assisted Treatment 
The disadvantages of Methadone include:  
• Daily dosing  
• Limited or no access to local programs  
• Risks of combining with other medications 
• Highly stigmatized  
• Can lead to cardiac issues  
(Williams, 2018) 
The disadvantages of Suboxone include:  
• Risks of painful withdrawal  
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• Street value 
• Stigma 
• Patients can misuse and abuse  
• Requires DEA Waivered clinician  
(Williams, 2018) 
The disadvantages of Vivitrol include:  
• Hard to find trained providers  
• Insurance issues  
• No pain relief  
• Lowers tolerance  
• Less effective in oral pill form  
(Williams, 2018) 
Success Rates of MAT- Suboxone 
People addicted to prescription painkillers reduce their opioid abuse when given sustained 
treatment with the medication buprenorphine plus naloxone (Suboxone), according to research 
published in The Archives of General Psychiatry and conducted by the National Institute on 
Drug Abuse (NIDA), part of the National Institutes of Health. The study, which was the first 
randomized large scale clinical trial using a medication for the treatment of prescription opioid 
abuse, also showed that the addition of intensive opioid dependence counseling provided no 
added benefit. (NIDA 2007) 
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"The study suggests that patients addicted to prescription opioid painkillers can be effectively 
treated in primary care settings using Suboxone," said NIDA Director Nora D. Volkow, M.D. 
"However, once the medication was discontinued, patients had a high rate of relapse — so, more 
research is needed to determine how to sustain recovery among patients addicted to opioid 
medications." (NIDA 2007) 
Pain medications are beneficial when used as prescribed, but they have significant abuse 
liability, especially when taken for non-medical reasons. This study examined whether the FDA-
approved medication Suboxone could help combat this growing problem. Suboxone is a 
combination of buprenorphine to reduce opioid craving plus naloxone, which causes withdrawal 
symptoms in someone addicted to opioids if Suboxone were taken by a route other than orally, as 
prescribed. This combination was specifically designed to prevent abuse and diversion of 
buprenorphine and was one of the first to be eligible for prescribing under the Drug Addiction 
Treatment Act, which permits specially trained physicians to prescribe certain FDA approved 
medications for the treatment of opioid addiction. (NIDA 2007) 
Most studies examining treatments for opioid dependence have been done with heroin-addicted 
patients at methadone clinics, so there have been little data on treatment for patients addicted to 
prescription painkillers, especially in the offices of primary care doctors. To help address this 
issue, NIDA’s Clinical Trials Network launched the Prescription Opioid Addiction Treatment 
Study (POATS) in 2007, which took place at 10 treatment sites around the country. 
"Despite the tremendous increase in the prevalence of addiction to prescription painkillers, little 
research has focused on this patient population," said Roger Weiss, M.D., of Harvard Medical 
School, Boston, and the lead author of the study. “This is the first large-scale study to examine 
RUNNING HEAD: MEDICATION-ASSISTED TREATMENT 37 
treatments exclusively for people who were abusing prescription painkiller medications and were 
treated with buprenorphine-naloxone, which can be prescribed in a physician's office." (NIDA 
2007) 
In the study, more than 600 treatment-seeking outpatients addicted to prescription opioids 
received Suboxone in combination with brief standard medical management, in which physicians 
evaluated treatment effectiveness and recommended abstinence and self-help participation. Half 
of the participants also received varying intensities of addiction counseling as provided by 
trained substance abuse or mental health professionals. (NIDA 2007) 
Results showed that approximately 49 percent of participants reduced prescription painkiller 
abuse during extended (at least 12-week) Suboxone treatment. This success rate dropped to 8.6 
percent once Suboxone was discontinued. Reductions in prescription painkiller abuse were seen 
regardless of whether or not the patient reported suffering chronic pain, and participants who 
received intensive addiction counseling did not show better outcomes when compared to those 
who did not receive this additional counseling. (NIDA 2007) 
Success Rates of MAT- Methadone 
Methadone maintenance is more effective in reducing heroin use among addicts  
than a 180 -day detoxification program that included an array of counseling  
services, a UC San Francisco study has found. 
The objective of the study was to compare methadone maintenance-a widely used  
but controversial method of weaning heroin addicts off the drug—with an  
alternative treatment of psychosocially enriched 180 day methadone assisted  
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detoxification. Methadone maintenance resulted in lower heroin use rates and  
fewer drug- related HIV risk behaviors, such as sharing needles. The study  
results will be published in the March 8 issue of the Journal of the American  
Medical Association. 
“Methadone maintenance is controversial,” said Sharon Hall, PhD, lead author of   
the study and UCSF professor in residence and vice-chair of psychiatry. “People  
don’t like it because it is continued provision of an addicting drug. When   
people come on methadone maintenance, they may stay on it for several years.  
The idea of the study was to do a comparison to find a method that was as   
effective but didn’t involve indefinite treatment with an addicting drug.”  
Methadone maintenance has been used to treat heroin addiction since 1964, Hall  
said. Heroin is a short- acting opiate, Hall explained, meaning it produces a  
high and a withdrawal effect rapidly. Methadone is a slower acting—and  
legal—opiate. It works by stabilizing heroin users so that they do not have a  
heroin -induced euphoria or suffer from severe withdrawal symptoms. 
The study enrolled 179 participants who were assessed monthly for a year. A  
urine specimen was collected each time. 
Those in the methadone maintenance part of the study received stable doses of  
methadone. Participants also attended one hour per week of substance abuse  
group therapy for the first six months and one hour per month of individual  
therapy.  
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Those in the 180 -day detoxification program received 120 days of methadone  
treatment, followed by 60 days of methadone dose reduction until they were no  
longer taking methadone. They also received a host of drug counseling services.   
During the first six months, participants were required to attend two hours per  
week of substance abuse group therapy, one hour per week of cocaine group  
therapy if they were found to also be addicted to that drug, and a series of  
one- hour substance abuse education classes held weekly. They also attended  
weekly individual therapy sessions. During the last seven months of the study,  
participants were offered aftercare treatment that included weekly individual  
and group psychotherapy and liaison services with the criminal justice system,  
medical clinics and social service agencies. 
Methadone maintenance was found to retain more patients and be more effective  
in decreasing heroin use, though use was still high in both groups. Also, the  
study found that those addicted to cocaine were more likely to drop out of the  
180-day program than the methadone maintenance program. 
“I think the results came out the way they did because heroin is a very   
addicting drug and we need pharmacological tools at this point to fight that   
addiction,” Hall said. “It’s not enough to just provide psychosocial services   
when we lose methadone. There are two ways the field could change. One is to  
develop more sophisticated pharmacological treatments for heroin addiction that   
have less addiction potential. Another thing we need to think about is  
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developing psychosocial interventions targeting what methadone patients need  
like legal and vocational services.” 
Hall added that one of the reasons the counseling services offered as part of  
the 180- day detoxification program did not lower heroin use might be because  
they were too general. 
“The other thing this study points out is that a long time ago methadone  
maintenance clinics had many more services than they do now,” she said. “And   
perhaps that’s one of the reasons the 180 day detoxification didn’t work. The   
services were limited in scope. We didn’t have legal or vocational services or  
family therapy. Many methadone programs have lost funding for these types of  
services and we have yet to see what a methadone program looks like that has   
them.” 
Success Rates of MAT- Vivitrol 
Recent research indicates that extended release naltrexone also known as Vivitrol, resulted in a 
lower rate of opiate relapse when paralleled to the usual treatment in a mainly male and minority 
people. The study participants were on an outpatient basis, voluntary participants with criminal 
justice involvement and opioid abstinence.  
The National Institute on Drug Abuse, a government organization that is part of the National 
Institutes of Health (NIH) co-sponsored a large, multisite, randomized trial to test the 
effectiveness of extended-release naltrexone among community-dwelling criminal justice 
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offenders who were at high risk for opioid relapse and other related adverse outcomes. The co-
sponsor was Alkermes, the manufacturer of the product. 
The report can be accessed at: Lee JD et al. “Extended-release naltrexone to prevent opioid 
relapse in criminal justice offenders.” N Eng J Med 2016; 374:1232-42. 
The authors stated that opioid dependence disproportionately affects U.S. criminal justice system 
populations. Relapse back to drug addiction and opioid overdose deaths occur at higher rates 
after release from incarceration. 
METHODS 
The trial involved five sites, all independently funded and using a common collaborative 
protocol. The sites were: 
1. University of Pennsylvania 
2. New York University School of Medicine  
3. Bellevue Hospital Center 
4. Brown University  
5. Rhode Island Hospital 
6. Columbia University  
7. Friends Research Institute 
The trial was open label without placebo control. It evaluated a 24-week course of Vivitrol 
compared with the usual treatment, such as counseling for community treatment programs for the 
prevention of opiate relapse among adults who had a history of opiate dependence and a 
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preference for opiate free rather than medication assisted treatment programs, and who were 
sober from opiates at the time of the study. (Lee JD et al, 2016) 
The main result was the time to an opiate relapse event, being outlined as 10 days or more of 
opiate use in 28 days as evaluated by self-report and by urine drug screens obtained every two 
weeks. A positive urine screen was processed as 5 days of opiate use. (Lee JD et al, 2016) 
Secondary results of attention include rates of alcohol and noon opiate drugs, risk of HIV, 
arrests, incarcerations, and overdose. (Lee JD et al, 2016) 
RECRUITMENT 
The study engaged adult volunteers who were criminal offenders with a background of opiate 
use. It includes 153 participants that were allotted to Vivitrol and 155 that were allocated to the 
usual rehab treatment groups. (Lee JD et al, 2016) 
The average age of all the subjects was 44 years old, with 85% of participants being male. All 
participants reported their history of opiate use, and 34% reported using heroin or another opiate 
in the 30 days prior. (Lee JD et al, 2016) 
Doctors and nurses dispensed Vivitrol via injection. Vivitrol was administered at 380 milligrams 
every four weeks, intramuscularly. Participants in the opposing treatment group received similar 
counseling, education on the prevention of relapse, overdose, and encouragement for community 
participation. (Lee JD et al, 2016) 
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Appointments followed screening, every two weeks for a 24-week treatment phase. After 
treatment follow up appointments were scheduled at weeks 27, 52, and week 78 including urine 
drug screens and patient reporting of opiate and any other drug use. (Lee JD et al, 2016) 
STUDY RESULTS 
1. During the 24-week treatment phase, the amount of time to relapse was considerably 
lengthier at 10.5 weeks in the Vivitrol group than was in the other treatment group at 5.0 
weeks. 
2. Relapse was identified in 66 patients in the Vivitrol group, as paralleled to 99 in the usual 
treatment group.  
3. The was a 74% rate of negative urine drug screens throughout the 24-week treatment and 
56% in the usual treatment group. At one year after treatment, rates of opiate negative 
urine drug screens were equivalent at 46% in both groups. 
 (Lee JD et al, 2016) 
SUMMARY 
The study indicated that Vivitrol ensued in a lower rate of opiate relapse than the rate was with 
usual treatment. The study did not compare Vivitrol with the regular of opiate agonist that is in 
medication assisted treatment.  
Suboxone Withdrawal  
Throughout withdrawal, the body is performing a lot of exertion. Therefore, one can 
anticipate to go through physical symptoms as you suffer from the detox process. Also, a 
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person’s mental health issues may emerge. Some detox and treatment facilities offer expert 
assistance in handling Suboxone withdrawal symptoms. Adequate treatment centers aim to make 
your detox as easy as is possible. Some of the most common physical symptoms of detox are: 
• Hot and Cold episodes   
• Skin Irregularities 
• Fatigue/Tiredness  
• Muscle Pain and Discomfort  
• Cravings for drugs 
• Sweating  
• Nausea  
• Vomiting  




The usual symptoms of detox are: 
• Irritability  
• Depression  
• Suicidality  
• Anxiety  
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In addition to depression and anxiety, withdrawal may trigger dormant mental health issues to 
ascent. Such as, when a female is using Suboxone maintenance for 10 years because it helps her 
thoughts of irritation and void. While detoxing from the Suboxone, she be reminded of these 
feelings without the numbing effects of Suboxone. Perhaps she is struggling with a personality 
disorder for numerous years without any idea about her diagnosis. These thoughts could be 
disturbing, if she has never sought help from a professional who is able postulate material and 
education about the motives following these feelings. (Nova 2018) 
Suboxone Withdrawal Timeline 
 Paralleled with other opiates, Suboxone does take more time to affect your body and will remain 
effective for a longer period. The time connected with opiate withdrawal is different for 
everyone. Since Suboxone is long acting, the symptoms of withdrawal will not surface as fast as 
they will when with drawling from other opiates. This will make withdrawal from Suboxone 
more challenging. (Nova 2018) 
Withdrawing from Suboxone will neither take place all at once or struggle on endlessly. It is 
more like a many step procedure. The following timeline indicates when symptoms cultivate 
during the detox progression. These times may differ for everyone, contingent on their 
distinctive body chemistry.  (Nova 2018) 
• Days 1 – 3: Physical indicators begin to appear within 12 hours after the last use of 
Suboxone. Muscle pain, nausea and diarrhea are common.  
• Days 4 – 7: Patients may suffer from insomnia as the system eradicates the Suboxone. 
Anxiety and irritability are common at this stage. 
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• Weeks 2 – 4: After week one, many people become depressed.  
• Month 2+: Relapse prevention is critical at this stage. Cravings for Suboxone may happen 
years after last use of the drug.  
(Nova 2018) 
Coping with Suboxone Withdrawal Symptoms 
There are many approaches to assist with suboxone withdrawal. Some may be treated at home, 
while others may only be accessible in a medical detox program. Counselors are able to assist, 
classify and survive any emotions that may be felt during withdrawing. Physicians that have 
knowledge of addiction know how to treat Suboxone withdrawal, and can help you towards the 
best treatment and medications. Persons should involve themselves in some of these healthy 
habits: 
• Exercise  
• Eating a balanced diet 
• Hydration 
•  Social Interaction  
• Fun Activities 
Whether at home or in a medical detox program, patients could profit from using some over the 
counter medication. Some common medications that may help cope with Suboxone withdrawal 
include: 
• Over the counter painkillers such as Tylenol  
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• Anti-nausea medications  
• Stomach settling remedies such as Sprite or Ginger Ale  
• Antacids  




 Methadone Withdrawal 
Symptoms of methadone withdrawal, typically start to appear within 24-36 hours after your last 
dosage of the medication. The detox process is supervised by a physician. The duration of the 
process varies for every person, and it could last from 2-3 weeks up to 6 months. 






• watery eyes 
• runny nose 
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• yawning 
• trouble sleeping 
In the beginning withdrawal symptoms may feel like the flu. Unlike with the flu, withdrawal 
symptoms can remain severe for several days. Symptoms may worsen after three days. 
Including: 
• muscle aches and pains 
• goosebumps 





• drug cravings 
The symptoms will be at their peak during the first week. Some symptoms can last longer 
than a week. These include low energy, anxiety, insomnia, and depression. Withdrawal can cause 
so much discomfort that the risk of returning to the use of other opiates is very high. 
Consequently, some people discuss remaining on methadone but at a lower dose.  Once a person 
becomes more stable at a lower dose, another attempt to detox can be discussed. (Harris, 2000)  
MAT During Pregnancy  
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The American College of Obstetricians and Gynecologists (ACOG) acknowledges that medically 
supervised withdrawal can be considered an option under the care of a doctor that is experienced 
in perinatal addiction medicine and with the consent of the mother if she is not willing to begin 
MAT. (ACOG, 2017) 
“Concern about medication-assisted treatment must be weighed against the negative effects of 
ongoing misuse of opioids, which can be much more detrimental to mom and baby,” said lead 
Committee Opinion author, Maria Mascola, M.D. “Medication-assisted treatment improves 
adherence to prenatal care and addiction treatment programs and has been shown to reduce the 
risk of pregnancy complications. And while neonatal abstinence syndrome is often seen in 
infants who have been exposed prenatally to opioids, it is important to remember that it is an 
expected and treatable condition that has not been found to have any significant effect on 
cognitive development.” (ACOG, 2017) 
“Opioid Use and Opioid Use Disorder in Pregnancy,” provides an up-to-date summary of 
treatment options, like methadone and suboxone. This will allow providers to offer better care 
for pregnant mothers suffering from opioid use disorder. ACOG recommends that screening for 
the mother’s opiate use take place during the first prenatal care visit. Verbal screening is 
preferred over urine testing for initial screening because it allows for a more complete 
assessment of the mother’s opiate use disorder providing opportunity for conversation that may 
encourage lifestyle changes. Urine drug testing may also be used as an adjunct to screening, but 
does not detect all substances and can produce false-positives. (ACOG, 2017) 
 “The postpartum period is already a vulnerable time for new moms, in general, as they face the 
stresses of sleep deprivation, caring for a newborn, and possibly symptoms of postpartum 
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depression,” said Mascola. “Women with opioid use disorder are dealing with all those things in 
addition to the challenges of their addiction, which—without treatment and support—can often 
lead to relapse. These guidelines are meant to help ob-gyns assert themselves in the care of their 
patients, so that they can make a lasting difference in their lives.” (ACOG, 2017) 
Conclusion 
The use of medications to treat substance use disorders has emerged as a significant part 
of the treatment methods available to medical practitioners.  The data in this paper has been 
presented to show the benefits and barriers associated with using several types of medication-
assisted treatment to treat opiate use.  Providing an overview including the pros and cons of the 
three drugs approved by the FDA for the treatment of opioid dependence: Buprenorphine, 
Methadone, and Naltrexone. In treatment of addiction, medications are used to reduce the 
intensity associated with withdrawal symptoms, reduction of cravings for the substance, and help 
reduce the chance of continued use or relapse. 
 Opioid treatment programs provide medication-assisted treatment to individuals who 
have been diagnosed with an opioid use disorder from a qualified professional.  Opioid treatment 
programs offer an array of services. The purpose of their services include reducing, eliminating, 
or preventing the use of illicit drugs; as well as reducing potential criminal activity and the 
spread of infectious diseases.  The substance abuse treatment field has been challenged to 
implement evidence-based practices.  There has recently been a dramatic increase in the number 
of interventions for substance use prevention and medication-assisted treatment is one of those 
interventions.     
All three of these treatment options have been proven to be safe and effective when 
combined with counseling and psychosocial support.  Some individuals believe that people who 
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seek treatment options for Opioid Use Disorders should be offered access to all three of these 
options.  Providing access to these options allows providers of services to collaborate with 
clients to select a form of treatment suited to their personal needs.   
Due to the chronic nature of Opioid Use Disorder, it is recommended that the need for 
continuing a medication-assisted treatment program be re-evaluated periodically.  There is not a 
maximum recommended duration of services for maintenance treatment.  Some patients may 
choose to continue treatment indefinitely.  All benefits and disadvantages should be considered 
by patients and their doctor when considering a treatment option best suited and personalized to 
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